Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Risk Factors for Early Remodelling in Severe Asthma in Children (P'tit-ASTHME)

15 juni 2016 bijgewerkt door: University Hospital, Bordeaux
  • Background: Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodeling. Consistent epidemiological data indicate that outcome of asthma in adults may be determined in early childhood. This may be due to bronchial remodeling, an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It appears very early in the natural history of the disease and involves increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that in severe asthma, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis. Moreover, we have also shown that immature human, non-asthmatic airway smooth muscle cells (ASMC) proliferate to a greater extent than normal adult ASMC, in a similar fashion to adult asthmatic ASMC. Immature ASMC may thus have great potential to stimulate airway remodeling. We thus hypothesized that remodeling is an early process and certain characteristics of ASMC in severe preschool asthma may predispose such children to persistent remodeling with airway obstruction later in life.
  • Purpose: To investigate prognostic factors of airway remodeling in preschool children, with special attention to ASMC proliferation (mitochondrial mass & biogenesis).
  • Methods: In the initial phase of the project, 75 severe asthmatic preschool children (<5 yr) will be prospectively recruited from the "CHU de Bordeaux" and the "CHU de Toulouse" according to the "Haute Autorité de Santé" criteria. Inclusion visit will include written informed consent, asthma control evaluation, clinical examination, lung function testing (exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens from all subjects will be obtained by fiberoptic bronchoscopy at visit 2. Airway remodeling will be evaluated by morphological analysis. After smooth muscle mitochondria will be analyzed by electronic microscopy & immunoblotting. Comparison between the 2 groups will be performed by unpaired t tests for parametric data and x2-tests for non-parametric data. In the second phase of the project, patients will then be followed-up till the age of 7-10 yrs, when another bronchoscopy with biopsies will be performed.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

67

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Aquitaine
      • Bordeaux, Aquitaine, Frankrijk, 33000
        • CHU de Bordeaux
    • Languedoc-Roussillon-Midi-Pyrénées
      • Toulouse, Languedoc-Roussillon-Midi-Pyrénées, Frankrijk, 31026
        • Hopital des Enfants

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

1 jaar tot 5 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Asthmatic children

  • Parents (and possibly the child) who gave written informed consent.
  • Affiliated with a social security scheme.
  • Age from 1 to less than 5 years.
  • Severe persistent asthma according to the criteria of the National Health Authority (Annex I) or NEW PROPOSED CRITERIA (adapted ATS (42)):

Major criteria (> 1) Asthma control in mild to moderate level requiring

  1. A continuous or semi continuous (≥ 50% of the year) by oral corticosteroids
  2. A treatment with high doses of inhaled corticosteroids (> 500 micrograms / day of Beclomethasone, or equivalent (> 400 micrograms / day of Budesonide,> 200 micrograms / day of Fluticasone) for at least 6 weeks.

And

minor criteria (> 2)

  1. The need for an additional daily treatment (β2-agonists, long-acting, theophylline, anti-leukotrienes)
  2. Symptoms that require taking daily or almost daily of β2-agonists of short action
  3. persistent obstruction (FEV <80% PEF variability> 20%) (If reliable spirometry, usually> 5 years of age)
  4. One or more seeking care in emergency / year
  5. At least three short courses of oral corticosteroids / year
  6. Rapid Increases caused by the decrease of 25% of the dose of oral corticosteroids or inhaled
  7. ATCD of severe acute asthma who put in life-threatening

Non-asthmatic children

  • Non asthmatic child with indication of endoscopy:

    • Any endoscopy for a disease without acute or chronic inflammation in the biopsy area (≥1 to <5 years (1st part): congenital stridor, double aortic arch, foreign body removal inhaled, ...; ≥ 7 to ≤ 10 years ( 2nd component): inhaled foreign body removal, ...).
    • Parents (and possibly the child) who gave written informed consent.
    • Affiliated with a social security scheme.
  • Children not asthmatic postmortem (retrospective and prospective)

    • Age from 1 to under 5 (1st part) or aged 7 to 10 years (2nd part) on the death
    • Died without pulmonary pathology in the sampled area
  • Non asthmatic child with thoracic surgery:

    • Age from 1 to under 5 (1st part) or aged 7 to 10 years (2nd part).
    • Subject with pulmonary pathology, requiring thoracic surgery lobectomy, non-inflammatory in the sampled area.
    • Parents (and possibly the child) who gave written informed consent.
    • Affiliated with a social security scheme.

Exclusion Criteria:

Asthmatic children:

  • Subject having a severe exacerbation of asthmatic disease requiring hospitalization in the 3 weeks preceding their inclusion.
  • exclusion period on topic compared to another protocol.
  • Subject with significant co-morbidity associated with asthma not of any nature whatsoever
  • bronchial malformations (exclusion criterion ex post).
  • Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) in the 4 weeks preceding the survey.
  • chronic viral infections (hepatitis, HIV).
  • non-specific inclusion criteria to endoscopy:
  • Review of hemostasis abnormal,
  • Subject with a heart condition,
  • Subject is not fasted for over 6 hours.

Children without asthma:

  • Non-asthmatic children with indication of endoscopy:

    • asthma diagnosed by a doctor.
    • exclusion period on topic compared to another protocol.
    • Subject with significant co-morbidity associated with asthma not of any nature whatsoever.
    • bronchial malformations (exclusion criterion ex post).
    • Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) in the 4 weeks preceding the survey.
    • chronic viral infections (hepatitis, HIV).
    • non-specific inclusion criteria to endoscopy:
    • Review of hemostasis abnormal,
    • Subject with a heart condition,
    • Subject is not fasted for over 6 hours.
  • Children postmortem non-asthmatics:

    • asthma diagnosed by a doctor.
    • Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) within 4 weeks before sampling of tissue.
    • chronic viral infections (hepatitis, HIV).
  • Non-asthmatic children with thoracic surgery:

    • asthma diagnosed by a doctor.
    • exclusion period on topic compared to another protocol.
    • Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) within 4 weeks before sampling of tissue.
    • chronic viral infections (hepatitis, HIV).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Asthmatic children
Sham-vergelijker: Non-asthmatic children

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Evaluation of Airway remodeling (distance from the reticular membrane to the smooth muscle).
Tijdsspanne: 1 day
1 day

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: MICHAEL FAYON, Professor, University Hospital, Bordeaux

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 maart 2012

Primaire voltooiing (Werkelijk)

1 november 2015

Studie voltooiing (Werkelijk)

1 november 2015

Studieregistratiedata

Eerst ingediend

15 juni 2016

Eerst ingediend dat voldeed aan de QC-criteria

15 juni 2016

Eerst geplaatst (Schatting)

20 juni 2016

Updates van studierecords

Laatste update geplaatst (Schatting)

20 juni 2016

Laatste update ingediend die voldeed aan QC-criteria

15 juni 2016

Laatst geverifieerd

1 juni 2016

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren